The study, published Feb. 8 in Cell Chemical Biology, found the cancer drug rucaparib, used for ovarian, breast and prostate cancers, and its metabolite, M324 molecule, had a complete reduction of α-synuclein enzyme accumulation in Parkinson’s disease models. The enzyme is a major component of Lewy bodies.
“The study reported here highlights the importance of characterizing the activity of drug metabolites to comprehensively understand drug response in the clinic and exploit our current drug arsenal in precision medicine,” the study authors wrote.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
